0.1556SEK-1.52%Mkt Cap: 10.17M $P/E: —Today
Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins a…
Industry Peers
Diagnostics & Research$226.85BUSDP/E 33.1
$151.78BUSDP/E 38.6
$46.70BUSDP/E 37.9
$46.86BUSD
$44.35BUSDP/E 39.5
$44.14BUSDP/E 31.4
$41.03BUSDP/E 31.0
$40.83BUSDP/E 105.8
$30.95BUSDP/E 38.2
$28.55BUSDP/E 32.1
$26.80BUSDP/E 27.4
$26.68BUSDP/E 25.6
$21.92BUSD
$16.98BUSDP/E 35.8
$13.64BUSDP/E 25.3
$13.84BUSD
$13.33BUSDP/E 57.4
$9.51BUSDP/E 19.0
$8.69BUSDP/E 22.8
$8.93BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
Immunovia AB (LTS:0G8X) (Q2 2026) Earnings Call Highlights: Revenue Surges 300% as PancreaSure ... Immunovia AB (LTS:0G8X) reports strong commercial adoption with 27 high-risk surveillance programs using PancreaSure, while managing cash burn below guidance ahead of Medicare submission. | ||
Immunovia AB (IMMVF) Q4 2025 Earnings Call Highlights: Navigating Financial Challenges and ... Immunovia AB (IMMVF) outlines its strategic initiatives and financial hurdles as it advances the PancreaSure test and seeks broader market penetration. | ||
Immunovia AB (FRA:1YR) Q3 2025 Earnings Call Highlights: Transition to Commercial Stage with ... Immunovia AB (FRA:1YR) marks a pivotal shift with the Pancreassure test launch, despite challenges in securing widespread insurance coverage. | ||